ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Co-stimulation"

  • 2022 American Transplant Congress

    Cd137 on Host Dendritic Cells Fine-Tunes the Intesity of Donor T Cells in Systemic Alloinmmune Responses

    S. Park1, H. Cho2, B. Kwon3, J. Lee4, H. Park1, J. Park4, K. Park4, K. Yoo4

    1Department of Surgery, University of Ulsan College of Medicine, Ulsan, Korea, Republic of, 2University of Ulsan College of Medicine, Ulsan, Korea, Republic of, 3School of Biological Sciences, University of Ulsan, Ulsan, Korea, Republic of, 4Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, Korea, Republic of

    *Purpose: CD137 is a potent costimulatory receptor for CD8+ T cells but it also regulates dendritic cells (DCs) to suppress immune responses. In this study,…
  • 2022 American Transplant Congress

    TIGIT Agonism Ameliorates Costimulation Blockade-Resistant Rejection by Increasing Quantity and Quality of Graft-Infiltrating Foxp3+ Treg

    C. R. Hartigan, D. Liu, S. Laurie, M. L. Ford

    Emory University Transplant Center, Emory University, Atlanta, GA

    *Purpose: Belatacept-based immunosuppression confers fewer off-target toxicities compared to CNI but comes at a cost of increased incidence and severity of acute rejection, potentially due…
  • 2022 American Transplant Congress

    Selective CD28 Blockade Impacts T Cell Differentiation During Hematopoietic Reconstitution Following Lymphodepletion

    J. Habib, D. Liu, R. L. Crepeau, M. E. Wagener, M. L. Ford

    Emory University, Atlanta, GA

    *Purpose: Costimulation blockade targeting the CD28 pathway provides improved long-term transplant survival without the nephrotoxicity of calcineurin inhibitors. However, treatment with the CTLA-4Ig fusion protein…
  • 2022 American Transplant Congress

    Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression

    B. Sirandas, A. Chan, M. Eiting, T. Larson, C. Truax, L. Smith

    University of Utah Health, Salt Lake City, UT

    *Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…
  • 2022 American Transplant Congress

    Co-stimulation Patways Pd-1 (the Programmed Death 1) And Icos (the Inducible T Cell Co-stimulator) In Peripheral Mononuclear Cells Mesured By Flow Cytometry As A Possible Tool In The Follow-up And Diagnosis Of Kidney Transplant Rejection.

    M. A. Carmona-Escamilla

    Posgrado de Ciencias médicas, Universidad Nacional Autonoma de México, CDMX, Mexico

    *Purpose: Currently, the follow-up of KT in the clinic remains the creatinine levels, this is a highly specific, however, without sensitivity to determine diagnosis of…
  • 2022 American Transplant Congress

    Clinically Available Immunosuppressive Agents Prolong Pig-to-Primate Kidney Xenograft Survival

    I. J. Anwar1, Q. Gao1, I. DeLaura1, J. Yoon1, R. Baldi1, M. Youd2, K. Stiede2, K. Hall2, S. Knechtle1, J. Kwun1

    1Surgery, Duke Transplant Center, Durham, NC, 2eGenesis Inc, Cambridge, MA

    *Purpose: Most immunosuppressive regimens used in Pig-To-Primate Xenotransplantation contain anti-CD154 agents, compounds that are currently not FDA-approved. The aim of this study was to assess…
  • 2022 American Transplant Congress

    Longitudinal Characterization of Memory B Cells During Antibody Mediated Rejection Treated with Plasmapheresis, Bortezomib, and Belatacept in Heart Transplant Recipients

    F. Alkhunaizi1, M. Ellison2, V. Berrich1, M. Siegelin1, M. Szabolcs1, G. F. Sayer1, N. Uriel1, S. Restaino1, A. Chong3, A. Zeevi2, M. Habal1

    1Columbia University Medical Center, New York, NY, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3University of Chicago, Chicago, IL

    *Purpose: Donor specific antibodies (DSA) and antibody mediated rejection (AMR) continue to limit allograft longevity after heart transplant. Effective treatments are limited and often complicated…
  • 2022 American Transplant Congress

    Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study

    I. Tawhari1, P. Hallak1, S. Hartzell2, V. Mas3, P. Cravedi2, J. Leventhal1, J. Ansari1, L. Gallon1

    1Northwestern University, Chicago, IL, 2Mount Sinai, New York, NY, 3University of Maryland, Baltimore, MD

    *Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…
  • 2022 American Transplant Congress

    Renal Function at Five Years from a Randomized Multicenter Trial of Belatacept-Based CNI Free and Early Steroid Withdrawal Immunosuppression

    E. Yanqui1, H. Hames1, A. R. Shields1, T. Shi1, A. L. Christianson1, J. Kremer2, A. Govil1, R. R. Alloway1, E. S. Woodle1

    1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH

    *Purpose: BENEFIT and BENEFIT EXT trials have demonstrated that belatacept-based immunosuppression was associated with improved long term renal allograft function compared to cyclosporine-based immunosuppression. Similar…
  • 2022 American Transplant Congress

    Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients

    A. Rizvi1, M. Kueht2, S. Hussain3, J. Fair2, R. Ramirez4, A. Gamilla-Crudo5, M. Mujtaba5

    1Internal Medicine, Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX, 2Surgery, University of Texas Medical Branch, Galveston, TX, 3University of Texas Medical Branch, Houston, TX, 4Surgery, University of Texas Medical Branch at Galveston, Galveston, TX, 5University of Texas Medical Branch, Galveston, TX

    *Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…
  • 1
  • 2
  • 3
  • …
  • 30
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences